CIBC World Market
PTGX icon

CIBC World Market’s Protagonist Therapeutics PTGX Stock Holding History

CIBC World Market’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-87,000
Closed -$2.52M – 1339
2024
Q1 		$2.52M Buy
+87,000
New +$2.37M 0.01% 599

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

CIBC World Market's PTGX Position: Q2 2024 in Review

CIBC World Market sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 87,000 shares — an estimated $2.52M sold.

CIBC World Market first reported a position in PTGX in Q1 2024 and held it in 1 quarter. The position peaked at $2.52M in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • CIBC World Market reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CIBC World Market sold 87,000 Protagonist Therapeutics shares in Q2 2024, an estimated $2.52M.
  • CIBC World Market first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 1 quarter.
  • CIBC World Market's Protagonist Therapeutics position peaked at $2.52M in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on CIBC World Market's 13F filing for Q2 2024, filed 7 Aug 2024.